Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios

F Lucà, F Oliva, MG Abrignani, SA Di Fusco… - Journal of Clinical …, 2023 - mdpi.com
It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …

Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients …

UR Essien, B Singh, G Swabe, AE Johnson… - JAMA Network …, 2023 - jamanetwork.com
Importance Type 2 diabetes (T2D) and heart failure (HF) prevalence are rising in the US.
Although glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose …

Association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation: findings from the get with the guidelines–atrial …

UR Essien, K Chiswell, LA Kaltenbach… - JAMA …, 2022 - jamanetwork.com
Importance Oral anticoagulation (OAC) is underprescribed in underrepresented racial and
ethnic group individuals with atrial fibrillation (AF). Little is known of how differential OAC …

Oral anticoagulant switching in patients with atrial fibrillation: a scoping review

AR Adelakun, RD Turgeon, MA De Vera, K McGrail… - BMJ open, 2023 - bmjopen.bmj.com
Introduction Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF).
Several factors may cause OAC switching. Objectives To examine the phenomenon of OAC …

Out-of-pocket drug costs for Medicare beneficiaries with cardiovascular risk factors under the inflation reduction act

PR Narasimmaraj, A Oseran, A Tale, J Xu… - Journal of the American …, 2023 - jacc.org
Background High out-of-pocket prescription drug costs contribute to financial toxicity,
medication nonadherence, and adverse cardiovascular (CV) outcomes. Policymakers …

Correlation between changes in brand-name drug prices and patient out-of-pocket costs

BN Rome, WB Feldman, RJ Desai… - JAMA Network …, 2021 - jamanetwork.com
Importance List prices set by manufacturers for brand-name prescription drugs in the US
have been increasing faster than inflation, although confidential manufacturer rebates offset …

Indication-specific generic uptake of imatinib demonstrates the impact of skinny labeling

BS Walsh, AS Kesselheim, A Sarpatwari… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Generic competition can be delayed if brand-name manufacturers obtain
additional patents on supplemental uses. The US Food and Drug Administration allows …

Association between copayment and adherence to medications for pulmonary arterial hypertension

EM Schikowski, G Swabe, SY Chan… - Journal of the American …, 2022 - Am Heart Assoc
Background Pharmacologic treatment for pulmonary arterial hypertension (PAH) improves
exercise capacity, functional class, and hemodynamic indexes. However, monthly …

Patient out‐of‐pocket costs following the availability of biosimilar versions of infliximab

K Feng, AS Kesselheim, M Russo… - Clinical Pharmacology …, 2023 - Wiley Online Library
After market exclusivity ends for biologic drugs, biosimilars—follow‐on versions made by
other manufacturers—can compete with lower prices. Biosimilars have modestly reduced …

Impact of longitudinal data-completeness of electronic health record data on risk score misclassification

Y Jin, S Schneeweiss, D Merola… - Journal of the American …, 2022 - academic.oup.com
Background Electric health record (EHR) discontinuity, that is, receiving care outside of a
given EHR system, can lead to substantial information bias. We aimed to determine whether …